SK Life Science, Inc., the U.S. subsidiary of SK Biopharmaceuticals, is an innovative global pharmaceutical company focused on the research, development and treatment of central nervous system (CNS) disorders. The company has a pipeline of eight compounds in development for CNS disorders including epilepsy.
In 2020, SK life science launched XCOPRI (cenobamate tablets) CV.
We recognize the nearly 65 million people worldwide with epilepsy.
We’re inspired by you and dedicated to improving awareness and care.
“We are committed to listening to the unique needs of the epilepsy community and providing support for innovative programs that can help improve lives. We know progress requires a consistent, collective effort, and it is a privilege to recognize this dynamic community every day.”
As long as there are unmet needs in the epilepsy and the CNS community, we keep working. We explore the complex mysteries of the brain to find answers for patients, caregivers, and healthcare professionals, because you’re worth it.
Check out these resources we developed for the epilepsy community:
• Seize the Truth about Epilepsy Perceptions (STEP) Survey: In 2019, we fielded a nationwide survey conducted by Kantar Health of over 850 people including epilepsy patients, caregivers and healthcare providers, which revealed important disconnects among the three groups. These findings showed key areas that need to be addressed in order for open, honest discussions to take place. To learn more about the survey and its findings, view this infographic.
• S.T.E.P.S. Discussion Tool: Take the right S.T.E.P.S. to have stronger conversations with your healthcare provider and work together to reach your goals. Within the S.T.E.P.S. Discussion Tool, you will find useful information such as suggested questions and topics that can be used to guide your discussion, so together you and your healthcare provider can create a treatment plan that works for you.
• Ride Share Program: Results from a new survey conducted by Kantar Health on behalf of SK Life Science, Inc., reveal that for people with epilepsy, transportation can be a significant challenge. Some people may even be restricted from driving, depending on the severity of their seizures and where they live.
Through a partnership SK Life Science, Inc. and the Epilepsy Foundation are providing Uber vouchers to those with epilepsy and their caregivers as well as working to spread awareness about the many challenges the 3.4 million people in the United States living with epilepsy face every day. To learn more about the Ride Share program for people with epilepsy and their caregivers, go to www.epilepsy.com/rideshare.
We are proud of our sponsors and appreciate their continued support